{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T11:47:57Z","timestamp":1742644077393,"version":"3.37.3"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T00:00:00Z","timestamp":1646352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T00:00:00Z","timestamp":1646352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s12328-022-01616-6","type":"journal-article","created":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T16:10:17Z","timestamp":1646410217000},"page":"592-597","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A case of paradoxical response during anti-tuberculosis treatment in a patient with ulcerative colitis"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8808-5672","authenticated-orcid":false,"given":"Shuhei","family":"Hosomi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Sugita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Kanamori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Ominami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Otani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Kamata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumio","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuaki","family":"Nagami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Taira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,4]]},"reference":[{"key":"1616_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/apt.13847","volume":"45","author":"EJ Mao","year":"2017","unstructured":"Mao EJ, Hazlewood GS, Kaplan GG, et al. Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn\u2019s disease and ulcerative colitis. Aliment Pharmacol Ther. 2017;45:3\u201313.","journal-title":"Aliment Pharmacol Ther"},{"key":"1616_CR2","doi-asserted-by":"publisher","first-page":"e012567","DOI":"10.1136\/bmjopen-2016-012567","volume":"7","author":"Z Zhang","year":"2017","unstructured":"Zhang Z, Fan W, Yang G, et al. Risk of tuberculosis in patients treated with TNF-alpha antagonists: a systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2017;7:e012567.","journal-title":"BMJ Open"},{"key":"1616_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.5217\/ir.2018.16.1.17","volume":"16","author":"DI Park","year":"2018","unstructured":"Park DI, Hisamatsu T, Chen M, et al. Asian Organization for Crohn\u2019s and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management. Intest Res. 2018;16:17\u201325.","journal-title":"Intest Res"},{"key":"1616_CR4","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1086\/427941","volume":"40","author":"C Garcia Vidal","year":"2005","unstructured":"Garcia Vidal C, Rodriguez Fernandez S, Martinez Lacasa J, et al. Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin Infect Dis. 2005;40:756\u20139.","journal-title":"Clin Infect Dis"},{"key":"1616_CR5","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.jbspin.2011.01.003","volume":"78","author":"C Rivoisy","year":"2011","unstructured":"Rivoisy C, Amrouche L, Carcelain G, et al. Paradoxical exacerbation of tuberculosis after TNFalpha antagonist discontinuation: beware of immune reconstitution inflammatory syndrome. Jt Bone Spine. 2011;78:312\u20135.","journal-title":"Jt Bone Spine"},{"key":"1616_CR6","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1517\/14740338.2015.1009036","volume":"14","author":"G Murdaca","year":"2015","unstructured":"Murdaca G, Spano F, Contatore M, et al. Infection risk associated with anti-TNF-alpha agents: a review. Expert Opin Drug Saf. 2015;14:571\u201382.","journal-title":"Expert Opin Drug Saf"},{"key":"1616_CR7","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","volume":"390","author":"SC Ng","year":"2017","unstructured":"Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390:2769\u201378.","journal-title":"Lancet"},{"key":"1616_CR8","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1038\/ajg.2013.138","volume":"108","author":"AC Ford","year":"2013","unstructured":"Ford AC, Peyrin-Biroulet L. Opportunistic infections with anti-tumor necrosis factor-alpha therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol. 2013;108:1268\u201376.","journal-title":"Am J Gastroenterol"},{"key":"1616_CR9","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/1756-185X.12188","volume":"17","author":"SV Navarra","year":"2014","unstructured":"Navarra SV, Tang B, Lu L, et al. Risk of tuberculosis with anti-tumor necrosis factor-alpha therapy: substantially higher number of patients at risk in Asia. Int J Rheum Dis. 2014;17:291\u20138.","journal-title":"Int J Rheum Dis"},{"key":"1616_CR10","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"J Keane","year":"2001","unstructured":"Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098\u2013104.","journal-title":"N Engl J Med"},{"key":"1616_CR11","first-page":"4","volume":"4","author":"M Pai","year":"2016","unstructured":"Pai M, Behr M. Latent mycobacterium tuberculosis infection and interferon-gamma release assays. Microbiol Spectr. 2016;4:4\u20135.","journal-title":"Microbiol Spectr"},{"key":"1616_CR12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/jgh.14019","volume":"33","author":"DI Park","year":"2018","unstructured":"Park DI, Hisamatsu T, Chen M, et al. Asian Organization for Crohn\u2019s and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: Risk assessment. J Gastroenterol Hepatol. 2018;33:20\u20139.","journal-title":"J Gastroenterol Hepatol"},{"key":"1616_CR13","doi-asserted-by":"publisher","first-page":"183","DOI":"10.5217\/ir.2016.14.2.183","volume":"14","author":"J Singh","year":"2016","unstructured":"Singh J, Puri AS, Sachdeva S, et al. Rectal tuberculosis after infliximab therapy despite negative screening for latent tuberculosis in a patient with ulcerative colitis. Intest Res. 2016;14:183\u20136.","journal-title":"Intest Res"},{"key":"1616_CR14","first-page":"262","volume":"10","author":"CM Quinn","year":"2020","unstructured":"Quinn CM, Poplin V, Kasibante J, et al. Tuberculosis IRIS: pathogenesis, presentation, and management across the spectrum of disease. Life (Basel). 2020;10:262.","journal-title":"Life (Basel)"},{"key":"1616_CR15","doi-asserted-by":"publisher","first-page":"101863","DOI":"10.1016\/j.tube.2019.101863","volume":"118","author":"PM Cevaal","year":"2019","unstructured":"Cevaal PM, Bekker LG, Hermans S. TB-IRIS pathogenesis and new strategies for intervention: Insights from related inflammatory disorders. Tuberculosis (Edinb). 2019;118:101863.","journal-title":"Tuberculosis (Edinb)"},{"key":"1616_CR16","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.2217\/fmb.15.9","volume":"10","author":"PE Namale","year":"2015","unstructured":"Namale PE, Abdullahi LH, Fine S, et al. Paradoxical TB-IRIS in HIV-infected adults: a systematic review and meta-analysis. Future Microbiol. 2015;10:1077\u201399.","journal-title":"Future Microbiol"},{"key":"1616_CR17","first-page":"201","volume":"20","author":"S Watanabe","year":"2017","unstructured":"Watanabe S, Kaneko Y, Kawamoto H, et al. Paradoxical response with increased tumor necrosis factor-alpha levels to anti-tuberculosis treatment in a patient with disseminated tuberculosis. Respir Med Case Rep. 2017;20:201\u20134.","journal-title":"Respir Med Case Rep"},{"key":"1616_CR18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.14205\/2310-9386.2015.03.01.6","volume":"3","author":"T Matsumoto","year":"2015","unstructured":"Matsumoto T, Tanaka T. Continuation of anti-TNF therapy for rheumatoid arthritis in patients with active tuberculosis reactivated during anti-TNF medication is more beneficial than its cessation. J Infect Dis Ther. 2015;3:35\u20137.","journal-title":"J Infect Dis Ther"},{"key":"1616_CR19","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.crohns.2013.12.013","volume":"8","author":"JF Rahier","year":"2014","unstructured":"Rahier JF, Magro F, Abreu C, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;8:443\u201368.","journal-title":"J Crohns Colitis"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-022-01616-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-022-01616-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-022-01616-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T17:17:15Z","timestamp":1654190235000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-022-01616-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,4]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1616"],"URL":"https:\/\/doi.org\/10.1007\/s12328-022-01616-6","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"type":"print","value":"1865-7257"},{"type":"electronic","value":"1865-7265"}],"subject":[],"published":{"date-parts":[[2022,3,4]]},"assertion":[{"value":"12 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from the patient for this case report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}